1.Estimated rates of treatment failure in first-line antiretroviral treatment in Kinshasa: Case of the ACS AMO-Congo.
2.Gender Difference in Early Treatment Patients for Human Immunodeficiency Virus Type 1 Infection in Kinshasa, Democratic Republic of Congo.
3. Profile of antiretroviral treatment centers in kinshasa, democratic republic of congo.
4.Analyse Comparative des Taux Lipidiques Sériques des Personnes Infectées par le VIH à Kinshasa.
5. Comparative analysis of electrophoresis’ profile of sera proteins of people infected by hiv and people not infected by hiv in kinshasa.
6.Comparative analysis of serum protein electrophoresis’ profiles of people infected with HIV and those not infected with HIV in Kinshasa.
7.Estimated rates of treatment failure in first-line antiretroviral treatment in Kinshasa: Case of the ACS AMO-Congo.
8.Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV Type 1 Infected Patients attending Clinics in Kinshasa, Democratic Republic of Congo.
9.GENETIC DIVERSITY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN DEMOCRATIC REPUBLIC OF CONGO: A REVIEW OF AVAILABLE DATA.
10.Genetic Diversity of Human Immunodeficiency Virus Type 1 in the Democratic Republic of Congo: a review of available data.
11.Human Immunodeficiency Virus Type 1 and Type 2 Co-infection Rate in Kinshasa Patients.
12.Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad.
13.Implementation of a Classic Nested PCR DNA for HIV Diagnosis in Kinshasa.
14.Implementation of an In-House Quantitative Real-Time PCR for Determination of HIV Viral Load in Kinshasa.
15.Mise en place d’une PCR Quantitative Temps Réel pour la détermination de la Charge Virale VIH à Kinshasa.
16.Prevalence of Malaria Infection among People Living with HIV in Kinshasa.
17.Profil Epidémiologique Moléculaire de l'Inféction à VIH de Type 1 chez les patients naïfs de traitement à kinshasa.
18.POSTER PRESENTATION Open Access Profiles of opportunistic infections in people living with HIV followed at the Military Hospital of Kinshasa Reference (Camp Kokolo), DRC.
19.Suivi des patients VIH positifs traités par la Médecine Traditionnelle à Kinshasa : étude rétrospective des dossiers des patients suivis au Centre BONKOKO.
20.Use of Dried Blood Spot to Improve the Diagnosis and Management of HIV in Resource-Limited Settings.
21.Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa.
22.Comparison of 3 Tests for Plasma HIV-1 RNA Quantitation of Non-B Subtypes in Patients Infected with HIV-1 in N’Djamena-Chad: Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0, Abbott m2000 RealTime and Generic HIV Viral Load® Assays.
23.Correlation between Sequencing Results from Liquid Plasma and Dried Plasma Spot (DPS) for Determination of HIV Type 1 Non-B Subtypes.
24.Détection des anticorps anti-VIH chez les donneurs de sang bénévoles recrutés dans les églises de Kinshasa..
25.Estimation of Clinical, Immunological and Virological Failure of First Line Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo.
26.Evaluation of the Effectiveness of the Cotrimoxazole and Antiretrovirals Association among Adult People Living with HIV: Case of Pilot Health Center and Maternity of Masina/Kinshasa from 2011 to 2016.
27.Evolution of Subtypes of the Human Immunodeficiency Virus Type 1 in Kinshasa over the Last 30 years: Documentary Review from 1985 to 2015.
28.Gender Difference in Early Treatment Patients for Human Immunodeficiency Virus Type 1 Infection in Kinshasa, Democratic Republic of Congo.
29.Immunologic and Virological Profile of Older Adult Patients Infected by the Human Immunodeficiency Virus starting Treatment in Kinshasa, Democratic Republic of Congo.
30.Implication of Neighbors in the Genetic Diversity of the Human Immunodeficiency Virus Type 1 in the Democratic Republic Of Congo.
31.Infection with Hepatitis B and C Virus in the Democratic Republic of Congo: A Public Health Problem.
32.Involvement of the Genetic Diversity of HIV-1 in the Virological Treatment Failure of First Line Antiretroviral in Kinshasa.
33.Mobile applications: effective tools against HIV in Africa.
34.Molecular and Virological profile of Professional Sex Workers (PSW) and their Partners at the beginning of ARV Treatment at IST Matonge in Kinshasa.
35.Molecular epidemiology of human immunodeficiency virus type 1 and therapeutic monitoring of patients treated in Kinshasa/Democratic Republic of the Congo.
36.Sociodemographic and Anthropometric Profile of Positive HIV Patients in Early Traditional Treatment: Case of the Bonkoko Center.
37.UV Visible Spectrophotometric Determination of the Quality of Antiretroviral Drugs Distributed in Kinshasa.
38.Vertical Transmission Rate of HIV from Seropositive Mothers Followed in the Different Care Centers in Kinshasa from 2010 to 2015.
39.Virological response, HIV 1 drug resistance mutations and genetic diversity among patients on first line antiretroviral therapy in N’Djamena, Chad: findings from a cross sectional study.
40.Misconceptions about HIV infection in Kinshasa (Democratic Republic of Congo): a case–control study on knowledge, attitudes and practices.
41.Factors that lead to changes in sexual behaviours after a negative HIV test: protocol for a prospective cohort study in Kinshasa.
42.Forced sexual intercourse and its association with HIV status among people attending HIV Voluntary Counseling and Testing in a healthcare center in Kinshasa (DRC).
43.Male condom use, multiple sexual partners and HIV: a prospective case-control study in Kinshasa (DRC).
44.Heterosexual oral and anal sex in Kinshasa (D. R.Congo): Data from OKAPI prospective cohort.
45.Utility Of POC Xpert HIV-1 Tests For Detection-Quantification Of Complex HIV Recombinants Using Dried Blood Spots From Kinshasa, D. R. Congo.
46.Perceptions of community sexual behaviors in Kinshasa: data from the OKAPI prospective cohort study.
47.High prevalence of antiretroviral resistance among HIV-1-infected adults in Kinshasa, Democratic Republic of Congo (OKAPI Cohort).
48.INFORMATION ABOUT HIV/AIDS IN KINSHASA(DRC): SOURCES, MESSAGES AND ASSOCIATED KNOWLEDGE, ATTITUDES AND BEHAVIOURS.
49.Effect of alcohol on sexual risk behaviors: Data from OKAPI prospective cohort study.
50.Forced sexual intercourse among women receiving HIV Voluntary Counseling and Testing in a healthcare center in Kinshasa and its association with HIV.
51.OKAPI* cohort: Observational Kinshasa AIDS Prevention Initiative Sexual behaviors, HIV subtypes and ARV resistance in HIV Voluntary Counseling and Testing patients..
52.HIV-related misconceptions in the D.R.Congo. Data from the OKAPI prospective cohort.
53.Reasons for attending HIV Voluntary Counseling and Testing: Data from OKAPI cohort study in Kinshasa.
54.Oral and anal sex: Data from OKAPI cohort (D.R.Congo).
55.Forced sex in Kinshasa: Data from OKAPI prospective cohort study.
56.Young people attending HIV Voluntary Counseling and Testing in Kinshasa: Data from OKAPI cohort study.
57.Baseline predictors for being lost to follow-up in OKAPI prospective cohort study.
58.RAPPORT D’ENQUETE : ETUDE CAP SUR LA SANTE SEXUELLE ET REPRODUCTIVE DES ADOLESCENTS ET JEUNES VIVANT AVEC VIH DANS LES PROVINCES DE KINSHASA ET KONGO CENTRAL EN 2020..